Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 22.8% during the third quarter, Holdings Channel.com reports. The firm owned 16,335 shares of the biopharmaceutical company’s stock after selling 4,827 shares during the quarter. Alnylam Pharmaceuticals accounts for approximately 1.0% of EFG Asset Management North America Corp.’s portfolio, making the stock its 17th biggest position. EFG Asset Management North America Corp.’s holdings in Alnylam Pharmaceuticals were worth $7,444,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Root Financial Partners LLC bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $25,000. Salomon & Ludwin LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $27,000. ORG Partners LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 70.2% in the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 33 shares in the last quarter. Quent Capital LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $39,000. Finally, Hilltop National Bank acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $41,000. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ALNY shares. Piper Sandler reaffirmed an “overweight” rating and set a $489.00 price target (up from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Leerink Partners decreased their target price on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research note on Monday, December 15th. Truist Financial lowered their target price on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Needham & Company LLC upped their price target on shares of Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a report on Monday, January 12th. Finally, Jefferies Financial Group reduced their price objective on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $485.21.

Alnylam Pharmaceuticals Trading Up 0.9%

Shares of NASDAQ ALNY opened at $361.35 on Tuesday. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The company has a market cap of $47.74 billion, a price-to-earnings ratio of 1,505.63 and a beta of 0.32. The business has a fifty day simple moving average of $407.93 and a 200-day simple moving average of $424.25.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,510 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the transaction, the executive vice president directly owned 29,728 shares in the company, valued at $10,787,399.36. This trade represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the transaction, the executive vice president directly owned 21,264 shares in the company, valued at approximately $7,874,697.12. This trade represents a 9.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 56,955 shares of company stock valued at $24,072,733. Corporate insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.